Real world evaluation of Evusheld in prevention of COVID-19 in immunocompromised patients: An observational cohort study
Recommended Citation
Channey S, Kale-Pradhan P, Sharma M, Lebovic D, Giuliano C, Johnson L, and Bhargava A. Real world evaluation of Evusheld in prevention of COVID-19 in immunocompromised patients: An observational cohort study. Am J Med Sci 2025;371(3):255-258.
Document Type
Article
Publication Date
3-1-2026
Publication Title
The American journal of the medical sciences
Keywords
Humans, COVID-19, Male, Female, Immunocompromised Host, Middle Aged, Retrospective Studies, Aged, SARS-CoV-2, Adult, Pre-Exposure Prophylaxis, Antibodies, Monoclonal, Humanized
Abstract
BACKGROUND: Evusheld®, a combination of monoclonal antibodies Tixagevimab and Cilgavimab, was developed for pre-exposure prophylaxis (PrEP) of coronavirus disease 2019 (COVID-19) in immunocompromised patients. However, real-world long-term data on its effectiveness against SARS-CoV-2 Omicron variants remain limited.
METHODS: A retrospective cohort was conducted on patients ≥18 years old who received the Evusheld from December 1, 2021, to January 31, 2023, at six Ascension hospitals in Southeast Michigan. Patients included were those with active solid tumor and hematologic malignancies or undergoing immunosuppressive treatment, including CAR-T therapy, biologic agents, or high-dose corticosteroids (≥20 mg prednisone or equivalent per day for ≥2 weeks). Data collected included patient demographics, development of COVID-19 post-Evusheld, ICU length of stay (LOS), hospital LOS, ventilation requirement and duration, and mortality within six months post-therapy.
RESULTS: Among 663 patients screened, 316 were included after excluding duplicates and patients that did not receive the ordered Evusheld regimen. Among them, 204 patients received two doses of Evusheld and 112 received only one dose. In the two-dose group, 18 (8.8%) tested positive for COVID-19 within 180 days post-Evusheld, while 11 (9.8%) in the one-dose group tested positive. Notably, none of the COVID-positive patients in either group required hospitalization, mechanical ventilation, or succumbed to the disease.
CONCLUSIONS: Within six months of Evusheld administration, immunocompromised patients showed no episodes of rehospitalization, mechanical ventilation, or death, and experienced low rates of severe COVID-19.
Medical Subject Headings
Humans; COVID-19; Male; Female; Immunocompromised Host; Middle Aged; Retrospective Studies; Aged; SARS-CoV-2; Adult; Pre-Exposure Prophylaxis; Antibodies, Monoclonal, Humanized
PubMed ID
41276115
ePublication
ePub ahead of print
Volume
371
Issue
3
First Page
255
Last Page
258
